Hepatic hydrothorax:An update and review of the literature

This review considers the modern concepts of pathogenesis,diagnostic methods,and treatment principles of hepatic hydrothorax(HH).HH is the excessive(>500 mL)accumulation of transudate in the pleural cavity in patients with decompensated liver cirrhosis but without cardiopulmonary and pleural diseases.It causes respiratory failure which aggravates the clinical course of liver cirrhosis,and the emergence of spontaneous bacterial pleural empyema may be the cause of death.The information was collected from the PubM ed database,the Google Scholar retrieval system,the Cochrane reviews,and the reference lists from relevant publications for 1994-2016 using the keywords:"liver cirrhosis","portal hypertension","hepatic hydrothorax","pathogenesis","diagnostics",and"treatment".To limit the scope of this review,only articles dealing with uncomplicated hydrothorax in patients with liver cirrhosis were included.The analysis of the data showed that despite the progress of modern hepatology,the presence of HH is associated with poor prognosis and high mortality.Most patients suffering from it are candidates for orthotopic liver transplantation.In routine clinical practice,stratification of the risk for an adverse outcome and the subsequent determination of individual therapeutic strategies may be the keys to the successful management of the patient’s condition.The development of pathogenetic pharmacotherapy and optimization of minimally invasive treatment will improve the quality of life and increase the survival rate among patients with HH.

A fascinating presentation of hepatic hydrothorax

We report this case of a 43-year-old woman with hepatitis-C cirrhosis who presented with a large right sided pleural effusion complicated by hypoxic respiratory failure and altered mentation necessitating dependence on mechanical ventilation. The pleural effusion spontaneously resolved upon initiation of mechanical positive pressure ventilation and recurred almost immediately after weaning the patient off the ventilator. The preventilation, ventilation and post-ventilation chest X-ray films in chronological order present a striking visual demonstration of fluid dynamics and pathophysiology of hepatic hydrothorax, thereby obviating the need for a dedicated diagnostic test. We also report this case to highlight the treatment strategies for this often intractable complication.

Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax:A systematic review and cumulative meta-analysis

AIM:To assess the effectiveness of transjugular intrahepatic portosystemic stent shunt(TIPSS) in refractory hepatic hydrothorax(RHH) in a systematic review and cumulative meta-analysis.METHODS:A comprehensive literature search was conducted on MEDLINE,EMBASE,and Pub Med covering the period from January 1970 to August 2014.Two authors independently selected and abstracted data from eligible studies.Data were summarized using a random-effects model.Heterogeneity was assessed using the I2 test.RESULTS:Six studies involving a total of 198 patients were included in the analysis.The mean(SD) age of patients was 56(1.8) years.Most patients(56.9%) had Child-Turcott-Pugh class C disease.The mean duration of follow-up was 10 mo(range,5.7-16 mo).Response to TIPSS was complete in 55.8%(95%CI:44.7%-66.9%),partial in 17.6%(95%CI:10.9%-24.2%),and absent in 21.2%(95%CI:14.2%-28.3%).The mean change in hepatic venous pressure gradient post-TIPSS was 12.7 mm Hg.The incidence of TIPSS-related encephalopathy was 11.7%(95%CI:6.3%-17.2%),and the 45-d mortality was 17.7%(95%CI:11.34%-24.13%).CONCLUSION:TIPSS is associated with a clinically relevant response in RHH.TIPSS should be considered early in these patients,given its poor prognosis.

Evaluating factors associated with the risk of hydrothorax following standard supracostal percutaneous nephrolithotomy

Objective:To report our experience with supracostal percutaneous nephrolithotomy(SC-PNL)and evaluate factors which could predict the risk of hydrothorax following SC-PNL.Methods:We reviewed 347 patients who underwent SC-PNL from January 2011 to December 2019.Patients were assessed for demographic characteristics,indication for the supracostal access,level of supracostal access,anatomy of the kidney(normal or malrotated),site of the puncture in relation to the mid-scapular line(medial or lateral),and whether another subcostal tract for stone clearance was required or not.Patients were assessed for the incidence of hydrothorax and requirement of intercostal drain depending on the level of percutaneous access.In addition,a multivariable logistic regression analysis model was developed to identify factors which could predict the occurrence of hydrothorax following SC-PNL.Results:Of the 347 patients with SC-PNL,248(71.5%)underwent a supra-12th rib approach,while the rest needed a supra-11th(n=85;24.5%)or a supra-10th(n=14;4.0%)rib tract.Overall,17(4.9%)patients developed a hydrothorax,while an intercostal-drain was required in seven of these 17 patients for 48 h.None of the patients with a supra-12th rib puncture required an intercostal-drain.More than a third of the patients with a supra-10th puncture developed a hydrothorax(35.7%)and all of them required an intercostal drain.Factors such as anteriorly malrotated kidney(odds ratio[OR]=2.722;95%confidence interval[CI]=1.042-5.617,p=0.03),puncture medial to the mid-scapular line(OR=1.669;CI=0.542-1.578,p=0.03),and an access higher than the supra-12th level(OR=5.265;CI=1.292-9.342,p<0.001)proved to be independent predictors of hydrothorax following a SC-PCNL on multivariable analysis.Conclusion:Incidence of clinically significant hydrothorax requiring an intercostal-drain after SC-PNL is very low.Knowledge of the predicting factors will help to anticipate the risk of hydrothorax in a particular patient and take necessary peri-operative measures.

Bi-directional hepatic hydrothorax

A 59-year-old male with alcoholic cirrhosis presented to our hospital with an acutely painful umbilical hernia,and 4 mo of exertional dyspnea.He was noted to be tachypneic and hypoxic.He had a massive right sided pleural effusion with leftward mediastinal shift and gross ascites,with a tense,fluid-filled,umbilical hernia.Emergent paracentesis with drain placement and a large volume thoracentesis were performed.Despite improvement in dyspnea and drainage of 15 L of ascitic fluid,the massive transudative pleural effusion remained largely unchanged.He underwent a repeat large volume thoracentesis on hospital day 4.The patient subsequently developed a tension pneumothorax,which resulted in a dramatic reduction in the effusion.A chest tube was placed and serial radiographs demonstrated resolution of the pneumothorax but recurrence of the effusion.The radiographs illustrate the movement of fluid between the peritoneal and pleural cavities.In this case,the mechanism of pleural effusion was confirmed to be a hepatic hydrothorax via an unintended tension pneumothorax.Methods to elucidate a hepatic hydrothorax include Tc99m or indocyanine green injection into the ascitic fluid followed by its demonstration above the diaphragm.The unintended tension pneumothorax in this case additionally demonstrates bi-directional flow across the diaphragm.

Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax

BACKGROUNDHepatic hydrothorax (HH) is an uncommon and difficult-to-manage complicationof cirrhosis with limited treatment options.AIMTo define the clinical outcomes of patients presenting with HH managed withcurrent standards-of-care and to identify factors associated with mortality.METHODSCirrhotic patients with HH presenting to 3 tertiary centres from 2010 to 2018 wereretrospectively identified. HH was defined as pleural effusion in the absence ofcardiopulmonary disease. The primary outcomes were overall and transplant-freesurvival at 12-mo after the index admission. Cox proportional hazards analysiswas used to determine factors associated with the primary outcomes.RESULTSOverall, 84 patients were included (mean age, 58 years) with a mean model forend-stage liver disease score of 29. Management with diuretics alone achievedlong-term resolution of HH in only 12% patients. At least one thoracocentesis wasperformed in 73.8% patients, transjugular intrahepatic portosystemic shuntinsertion in 11.9% patients and 33% patients received liver transplantation within12-mo of index admission. Overall patient survival and transplant-free survival at12 mo were 68% and 41% respectively. At multivariable analysis, current smoking [hazard ratio (HR) = 8.65, 95% confidence interval (CI): 3.43-21.9, P < 0.001) and acute kidneyinjury (AKI) (HR = 2.91, 95%CI: 1.21-6.97, P = 0.017) were associated with a significantly increasedrisk of mortality.CONCLUSIONCirrhotic patients with HH are a challenging population with a poor 12-mo survival despitecurrent treatments. Current smoking and episodes of AKI are potential modifiable factors affectingsurvival. HH is often refractory of diuretic therapy and transplant assessment should beconsidered in all cases.

Successful treatment of hepatic hydrothorax: A case report

Rationale:Acute complications of cirrhosis can be life-threatening.One of the less common acute complications is hepatic hydrothorax whose medical management is rarely successful and is still controversial.Patient concerns:A 51-year-old patient presenting to the emergency room for a massive pleural effusion.Diagnosis:A hepatic hydrothorax with a placed chest tube whose removal was not possible.Interventions:Increased doses of diuretics with a strict salt-free diet.Outcomes:An improvement of the clinical state,with no recurrent pleural effusion up to one month.Lessons:Medical management of hepatic hydrothorax is possible.

Novel conservative treatment for peritoneal dialysis-related hydrothorax:Two case reports

BACKGROUND Peritoneal dialysis (PD) is an important renal replacement therapy for patientswith end-stage renal disease. PD-related hydrothorax is a rare but seriouscomplication in PD patients, produced by the movement of peritoneal dialysatethrough pleuroperitoneal fistulas. In previous reports, patients with hydrothoraxsecondary to PD were usually recommended to discontinue PD and transfer tohemodialysis (HD). Herein, we describe another method of managing thiscomplication—with an adjusted PD prescription and continuous drainage ofpleural effusion, patients could continue PD without recurrence of hydrothorax.CASE SUMMARY In this report, we present the medical records of 2 patients with hydrothoraxsecondary to PD. We recommended intermittent PD with continuous drainage ofpleural effusion. A type 18Ga soft catheter was placed to drain pleural effusion.Ultrasound-guided thoracentesis was performed, and the soft catheter was placedin the pleural cavity for a long period (3 mo and 2 mo, respectively). The pleuralcatheter was removed when no fluid was drained from the pleural cavity. Afterseveral months, pleuroperitoneal fistulas were closed in both patients and PD wascontinued. These patients did not transfer to HD, had no recurrence ofhydrothorax and were still treated with PD after 1 year.CONCLUSION These 2 case reports show that continuous drainage of pleural effusion with an18Ga soft catheter is a useful method for hydrothorax secondary to PD.

Human umbilical cord blood-derived mononuclear cell transplantation for umbilical hernia and hepatic hydrothorax in primary biliary cirrhosis

Cell therapy was proposed as a potential treatment intervention for liver cirrhosis recently due to the fact that the therapeutic protocol for primary biliary cirrhosis (PBC)-associated refractory umbilical hernia and hepatic hydrothorax is not well defined currently. We report herein the case of a 58-year-old woman who received routine treatments for PBC, which developed into an incarcerated hernia and uncontrolled hydrothorax. This subject’s condition was significantly improved and maintained stable condition after receiving human umbilical cord blood-derived mononuclear cell (CBMC) transplantation. Consequently, this new strategy may be a potential treatment option for the refractory umbilical hernia and hydrothorax caused by PBC. However, sufficient data from large-scale controlled and double-blinded clinical trials are needed to further confirm the treatment efficacy and longterm safety before this cell transplantation can be used as a regular therapy for liver cirrhosis.

Hepatic hydrothorax occurring rapidly after manual abdominal compression

肝的水疗院胸是经常引起呼吸机能障碍的肝肝硬化的相对很少发生却潜在地严肃的复杂并发症。为肝的水疗院胸的开发的几个假设被建议了通过在腹洞和肋膜的空格之间的小缺点解释腹水的 transdiaphragmatic 移动。然而，在几个小时以内的水疗院胸的快速的发展很少被遇到。另外，为进胸膜腔的腹水的快速的经过的原因的因素是未知的。这份报告与肝肝硬化描述一个病人在腹部的用手的压缩以后承受了水疗院胸的快速的开发。

Diagnostic Values of Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor for Benign and Malignant Hydrothorax

Background： Hydrothorax, as one of the common complications of malignant tumors, still cannot be sensitively detected in clinical practice, thus requiring a sensitive, specific method for diagnosis. The aim of this study was to analyze the correlation between levels of vascular endothelial growth factor （VEGF） and epidermal growth factor receptor （EGFR） in patients with benign and malignant hydrothorax. Methods： The contents of VEGF in the pleural effusion and serum of the patients with malignant pleural effusion （n = 35） and benign pleural effusion （n = 30） were detected by double antibody sandwich enzyme linked immunosorbent assay. The gene copy number level of EGFR in pleural effusion was detected by fluorescence in situ hybridization （FISH）. The points with the highest sensitivity and specificity were selected as the critical values to calculate the diagnostic value of the VEGF in pleural effusion and serum, and EGFR gene copy number in pleural effusion. Results： The contents of VEGF in pleural effusion and serum of patients with malignant hydrothorax were （384.91 ± 120.18）, and （129.62 ±46.35） ng/L, respectively, which were significantly higher than those of the patients with benign hydrothorax （207.97 ± 64.04）, （63.49 ± 24.58） ng/L （P 〈 0.01 ）. The sensitivity and specificity of detecting VEGF in pleural effusion were 80.0% and 96.7% （the boundary value was 297.06 ng/L）, respectively for diagnosing benign and malignant hydrothorax. The sensitivity and specificity of serum were 74.3% and 96.7%, respectively （the boundary value was 99.21 ng/L） for diagnosing benign and malignant hydrothorax. The diagnostic efficiencies of EGFR and VEGF in hydrothorax were similar. There was a significant correlation between EGFR and VEGF in hydrothorax （P 〈 0.01 ）. Conclusions： VEGF and EGFR play important roles in the formation of pleural effusion. VEGF differed significantly in benign and malignant pleural effusions, which contributed to differential diagnosis results of benign and malignant pleural effusions. It is feasible to detect the gene copy number of the pleural effusion cell mass EGFR by FISH technique. Joint detection can improve the diagnostic sensitivity.

Thoracoscopy for diagnosis and management of refractory hepatic hydrothorax

The prevalence of pleural effusion caused by hepatocirrhosis ranges from 0.4% to 30%. Some patients with hepatic hydrothorax （HH） fail to respond to aggressive medical management such as albumin application, diuretics, and thoracentesis, and remain refractory massive pleural fluid. The repeated suctions to relieve the symptoms such as respiratory distress are associated with significant hyponatremia and hypoalbuminemia caused by the large volumes of fluid loss. Review of the literature has revealed that, to date, no therapy is ideal. This report describes our experiments in treating HH of patients with cirrhosis and ascites by thoracoscopy and talc poudrage, to offer our efforts to approach the pathogenesis of HH and to explore the new therapeutic strategy.

肺淋巴管平滑肌瘤病一例并文献复习

肺淋巴管平滑肌瘤病(PLAM)发病率低,在临床上属于少见病,因其起病隐匿,无典型症状,影像学表现易与肺气肿混淆,在临床上容易漏诊、误诊。本例患者因咳嗽进行体检时偶然发现胸腔积液及双肺多发囊腔影,经肺活检明确诊断该病。本文通过对该病例的病史、辅助检查、诊断过程进行分析及对相关文献资料复习,总结出PLAM一些临床特征及治疗经验,以期提高广大医务工作者对该类疾病的诊疗水平。

卵巢甲状腺肿2例临床分析

卵巢甲状腺肿临床少见,表现形式多样,容易漏诊,现根据本科2例卵巢甲状腺肿的临床诊治情况,探讨卵巢甲状腺肿的诊断、治疗及预后,为早发现、早诊断、早治疗提供依据。回顾性分析2例卵巢甲状腺肿患者的临床资料,依据不同的临床症状及体征采用不同的影像学检查,进而确定手术治疗方式,并评价治疗效果及预后情况。2例患者虽然临床表现不同,影像学检查也差别较大,但手术标本提示病理结果相同,都诊断为卵巢甲状腺肿,都能通过手术获得良好的治疗效果。通过分析发现,卵巢甲状腺肿患者拥有不同的临床表现及体征,影像学检查结果明显不同,因此在临床诊治过程中要全面考虑、及时手术、术中快速病理,以便采取恰当的手术方式,争取较好的疗效。

胸腔积液外泌体miR-506-3p联合腺苷脱氨酶检测在结核性胸膜炎的早期诊断及预后评估中的价值

目的 分析胸腔积液外泌体miR-506-3p联合腺苷脱氨酶(adenosine deaminase,ADA)在结核性胸膜炎的早期诊断及预后评估中的价值。方法 选取2021年8月至2023年3月就诊于沧州市人民医院的90例结核性胸膜炎患者作为结核组,另选同期于沧州市人民医院就诊的50例非结核性胸膜炎(肺炎旁胸腔积液、恶性胸腔积液等)患者作为非结核组,对比两组临床资料与胸腔积液外泌体miR-506-3p、ADA水平,经多因素Logistic回归分析影响结核性胸膜炎发生的危险因素。根据治疗3个月后患者预后情况,将结核组分为预后良好组(72例)、预后不良组(18例),对比两组胸腔积液外泌体miR-506-3p、ADA水平。经Pearson相关性分析,并绘制受试者操作特征曲线(receiver operating characteristic curve,ROC曲线),分析胸腔积液外泌体miR-506-3p、ADA水平及二者联合预测结核性胸膜炎发生及患者预后的价值。结果 结核组患者胸腔积液ADA水平比非结核组高,胸腔积液外泌体miR-506-3p水平比非结核组低(P<0.05);经多因素Logistic回归分析发现,胸腔积液ADA水平高[OR=1.205(95%CI 1.105~1.313)]是结核性胸膜炎发生的危险因素(P<0.05),外泌体miR-506-3p水平高表达[OR=0.320(95%CI 0.158~0.658)]是结核性胸膜炎发生的保护因素(P<0.05);预后不良组患者胸腔积液ADA水平比预后良好组高,胸腔积液外泌体miR-506-3p水平比预后良好组低(P<0.05);绘制ROC曲线发现,胸腔积液ADA、外泌体miR-506-3p水平及二者联合预测结核性胸膜炎发生的曲线下面积(area under curve,AUC)为0.729(95%CI 0.640~0.818)、0.810(95%CI 0.738~0.883)、0.874(95%CI 0.818~0.930),预测结核性胸膜炎患者不良预后的AUC为0.892(95%CI 0.806~0.978)、0.924(95%CI 0.868~0.981)、0.942(95%CI 0.875~1.000);Pearson相关性显示,胸腔积液ADA与外泌体miR-506-3p水平呈负相关(r=-0.335,P=0.001)。结论 结核性胸膜炎患者胸腔积液外泌体miR-506-3p呈低表达、ADA呈高表达,二者之间为负相关,且miR-506-3p联合ADA可有效预测结核性胸膜炎患者不良预后的发生。

胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片法在病理检测的价值

目的探讨与分析胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片法在病理检测的价值。方法选取2019年3月—2022年9月在乌鲁木齐市中医医院诊治的92例胸腹水患者作为研究对象,所有患者都给予胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片法,都给予病理活检,判断诊断的价值。结果在92例患者中,胸腹水液基细胞学检测判断为恶性肿瘤54例,良性肿瘤38例,胸腹水液基细胞学检测诊断恶性肿瘤的敏感度与特异度分别为85.48%、96.67%。胸腹水沉淀物琼脂石蜡双包埋切片检测判断为恶性肿瘤55例,良性肿瘤37例,胸腹水沉淀物琼脂石蜡双包埋切片检测诊断恶性肿瘤的敏感性与特异性分别为88.71%、100.00%。胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片检测判断为恶性肿瘤61例,良性肿瘤31例,胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片检测诊断恶性肿瘤的敏感度与特异度分别为98.39%、100.00%。恶性肿瘤患者的人表皮生长因子受体2、突触素、嗜铬素A表达阳性率分别为40.32%、41.94%、43.55%,与良性肿瘤患者的10.00%、13.33%、10.00%相比有显著提高,差异有统计学意义(P<0.05)。胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片法对肿瘤良恶性的诊断敏感性高于单项检测,差异有统计学意义(P<0.05),不同检测方法的诊断特异性比较,差异无统计学意义(P>0.05)。ROC曲线分析显示,胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片法对肿瘤良恶性的诊断曲线下面积为0.883。结论胸腹水液基细胞学检测联合胸腹水沉淀物琼脂石蜡双包埋切片法在病理检测中的应用能提高诊断敏感度,还可保持非常高的诊断特异度,对患者的原发肿瘤良恶性判定具有很好的价值。

Video-assisted thoracoscopic surgery (VATS) for the treatment of hepatic hydrothorax:report of twelve cases

Background:Hepatic hydrothorax is defined as a significant pleural effusion in patients with liver cirrhosis and without underlying cardiopulmonary diseases. Treatment of hepatic hydrothorax remains a challenge at present. Methods:Herein we share our experiences in the treatment of 12 patients with hepatic hydrothorax by video-assisted thoracoscopic surgery(VATS) . Repair of the diaphragmatic defects,or pleurodesis by focal pleurectomy,talc spray,mechanical abrasion,electro-cauterization or injection was administered intraoperatively,and tetracycline intrapleural injection was used postoperatively for patients with prolonged(>7 d) high-output(>300 ml/d) pleural effusion. Results:Out of the 12 patients,8(67%) had uneventful postoperative course and did not require tube for drainage more than 3 months after discharge. In 4(33%) patients the pleural effusion still recurred after discharge due to end-stage cirrhosis with massive ascites. Conclusion:We conclude that the repair of the diaphragmatic defect and pleurodesis through VATS could be an alternative of transjugular intrahepatic portal systemic shunt (TIPS) or a bridge to liver transplantation for patients with refractory hepatic hydrothorax. Pleurodesis with electrocauterization can be an alternative therapy if talc is unavailable.

2017—2021年南阳市某医院胸、腹水培养的病原菌分布及耐药性分析

目的分析胸、腹水标本中的病原菌分布特点及对常用抗菌药物的耐药性,为临床医师抗感染治疗提供参考依据。方法回顾性分析2017年1月1日—2021年12月31日南阳市第一人民医院胸、腹水培养的病原菌分布和耐药性,使用梅里埃Vitek2–Compact自动细菌鉴定药敏仪、珠海迪尔DL-96细菌鉴定分析系统进行菌株鉴定和药敏试验,结果判读参照当年美国临床和实验室标准协会(CLSI)发布的行业标准。结果2074份胸、腹水培养标本,共分离出650株非重复病原菌,总阳性率为31.34%。996份胸水标本中分离出病原菌219株,阳性检出率为21.99%;1078份腹水标本中分离出病原菌431株,阳性检出率为39.98%。胸、腹水分离的病原菌中均以革兰阳性菌为主,分别占55.25%、48.96%,均以肠球菌属和葡萄球菌属为主;革兰阴性菌分别占36.07%、43.62%,主要为大肠埃希菌、肺炎克雷伯菌和鲍曼不动杆菌;真菌分别占8.68%、7.42%,均以白假丝酵母菌为主。三种主要的革兰阳性球菌对红霉素、青霉素的耐药率高于70.00%,对万古霉素、利奈唑胺和替考拉宁的耐药率为0。大肠埃希菌和肺炎克雷伯菌对氨苄西林、头孢唑林的耐药率最高,超出80.00%,大肠埃希菌对亚胺培南、美罗培南的耐药率低于3.00%,肺炎克雷伯菌对亚胺培南、美罗培南的耐药率高于25.00%,仅对替加环素、多黏菌素B较敏感;鲍曼不动杆菌对亚胺培南、美罗培南的耐药率高于40.00%,但对头孢哌酮/舒巴坦、替加环素比较敏感。结论胸、腹腔感染的病原菌复杂多样,以革兰阳性菌为主,常见病原菌的耐药情况相当严重。明确胸、腹腔感染的病原菌类别和耐药情况,对于临床医师的早期经验性抗感染治疗和医院感染的管控有极其重要的指导意义。

胸水和血清中腺苷脱氨酶与乳酸脱氢酶水平及比值在结核性胸膜炎诊断中的价值分析

目的 分析胸水和血清中腺苷脱氨酶(ADA)与乳酸脱氢酶(LDH)水平及比值在结核性胸膜炎诊断中的意义。方法 选取20例结核性胸膜炎患者作为观察组,另选取同期20例肝性胸水患者作为对照组。两组患者均进行胸水和血清中ADA与LDH水平检测,计算其相应的比值。比较两组患者胸水和血清中ADA水平及比值,胸水和血清中LDH水平及比值。结果 观察组患者的胸水腺苷脱氨酶(PADA)(68.50±1.02)U/L及PADA/血清腺苷脱氨酶(SADA)(3.13±1.40)均显著高于对照组的(3.55±0.98)U/L、(0.94±0.45), SADA(16.20±2.80)U/L低于对照组的(24.60±17.59)U/L,差异均有统计学意义(P<0.05)。观察组患者的胸水乳酸脱氢酶(PLDH)(418.00±201.40)U/L和PLDH/血清乳酸脱氢酶(SLDH)(3.44±2.27)均显著高于对照组的(52.50±46.60)U/L、(0.35±0.25), SLDH(203.00±40.70)U/L低于对照组的(254.50±58.00)U/L,差异均有统计学意义(P<0.05)。结论 结核性胸膜炎患者胸水和血清中的ADA、LDH比值显著高于肝性胸水患者,所以胸水和血清中的ADA与LDH比值在结核胸膜炎诊断中具有重要临床意义。

深部热疗配合胸腹腔内注射顺铂及甘露聚糖肽在恶性胸腹水中的疗效及对生活质量的影响

目的:探究深部热疗配合胸腹腔内注射顺铂及甘露聚糖肽在恶性胸腹水中的疗效及对生活质量的影响。方法:选择广州市中西医结合医院2020年9月-2022年1月收治的100例恶性胸腹水患者,按照随机数字表法将其分为对照组和观察组,各50例。对照组进行胸腹腔内注射顺铂及甘露聚糖肽治疗,观察组则进行深部热疗配合胸腹腔内注射顺铂及甘露聚糖肽治疗。比较两组的治疗总有效率、毒副反应发生率及治疗前后的生活质量[卡氏(KPS)评分及世界卫生组织生存质量测定量表简表(WHOQOL-BREF)评分]。结果:观察组的总有效率显著高于对照组,毒副反应发生率显著低于对照组,差异有统计学意义(P<0.05)。治疗前,两组的KPS评分及WHOQOL-BREF评分比较,差异无统计学意义(P>0.05);治疗后2、4周,观察组的KPS评分及WHOQOL-BREF评分显著优于对照组,差异有统计学意义(P<0.05)。结论:深部热疗配合胸腹腔内注射顺铂及甘露聚糖肽在恶性胸腹水中的疗效较好,有助于减轻相关毒副反应及提升生活质量,因此在恶性胸腹水患者中的应用价值相对较高。